N/A N=309 Hepatitis C Translating Initiatives for Depression Into Effective Solutions
Hepatitis C · Depression
Primary: Number of Patients Who Initiated Hepatitis C Antiviral Treatment Within 12 Months of Enrollment — 11; 7 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=21 Treatment of Acute Hepatitis C Virus in HIV Co-Infection
Hepatitis C · Human Immunodeficiency Virus · HIV Infections
Primary: Sustained Virologic Response (SVR) — 62 percentage of participants
Phase 2 N=229 Combination Therapy for Chronic Hepatitis C Infection
Hepatitis C, Chronic
Primary: The Proportion of Subjects Who Achieve Sustained Viral Response (SVR12) 12 Weeks After the Stop of Treatment Drugs — 100; 95; 95; 91.2 percentage of subjects
Phase 2 N=273 Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection
Chronic Hepatitis C
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 92.9; 96.2; 74.1; 100.0 percentage of participants
Phase 4 N=58 Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3
Hepatitis C
Primary: Virological Response (Intention to Treat) — 19; 21; 7; 2 participants
N/A N=130 Quality of Life During Treatment of Chronic Hepatitis C (P05278/MK-4031-336)
Hepatitis C, Chronic · Genotype 1 · HCV-1
Primary: Change From Baseline (BL) to Week 72 (WK72) in 36-Item Short-Form Health Survey (SF-36) Scores — 87.27; 87.33; -1.56; 81.71 score on a scale
Phase 2 N=24 Evaluation of Safety, Tolerability, and Antiviral Activity of Chlorcyclizine HCl in Patients With Chronic Hepatitis C
Chronic Hepatitis C
Primary: Change in Serum HCV RNA Viral Titer From Baseline to 28 Days — -0.46; -0.11 log IU/ml
N/A N=134 Hepatitis C Self-Management
Hepatitis C · Chronic Disease
Primary: Quality of Well-being Scale - Self-Administered (QWB-SA) — .534; .501; .600; .504 units on a scale
Phase 4 N=600 Community-based Treatment of Chronic Hepatitis C Monoinfection and Coinfection With HIV in the District of Columbia
HCV HIV
Primary: Number of Subjects Who Achieve Sustained Viral Response (SVR12) 12 Weeks After the Stop of Treatment Drugs — 516 Participants
Phase 2 N=129 A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients
Chronic Hepatitis C Infection
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 97.1; 96.3; 100; 100 percentage of participants
Phase 3 N=636 A Study to Evaluate Chronic Hepatitis C Infection
Chronic Hepatitis C Infection
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment — 96.4 percentage of participants
Phase 2 N=21 High-Dose Ribavirin and Peginterferon to Treat Chronic Hepatitis C Genotype 1
Chronic Hepatitis C
Primary: Sustained Virological Response, (HCV RNA Neg.) in Serum 24 Weeks Off Therapy. — 3 participants
Phase 2 N=72 Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816
Chronic Hepatitis C
Primary: Number of Participants With Sustained Virologic Response — 70 Participants
Phase 2 N=29 Peginterferon Alpha-2a and Ribavirin to Treat Hepatitis C in HIV-infected Patients
Hepatitis C · HIV Infections
Primary: Number of Participants With Sustained Virologic Response (SVR) — 11; 11 participants
Phase 2 N=36 Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients
Hepatitis C · HIV Infections
Primary: Participants With Viral Decline at Day 3 & 28 With Predictors of Post Treatment Response — 8 participants with post treatment svr
N/A N=366 Undiagnosed Hepatitis C Infection in an Urban Hospital
Hepatitis C
Primary: Point Prevalence of Hepatitis C Infection — 9 percentage of total subjects
Phase 3 N=1,050 Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment
Chronic Hepatitis c · Cirrhosis, Liver · Fibrosis, Liver
Primary: Progression of Liver Disease as Indicated by Death, Hepatic Decompensation, Hepatocellular Carcinoma, or for Patients With Noncirrhotic Fibrosis at Baseline, an Increase…
Phase 4 N=50 Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease
Chronic Hepatitis C
Primary: Change in Hepatitis C Virus RNA Levels During Phase I — 0.50; 0.70 log(IU/mL) — p=0.54
N/A N=49 A Retrospective Study of Real World Treatment Outcomes of Patients With Chronic Hepatitis C
Hepatitis C, Chronic
Primary: Sustained Virological Response (SVR): Percentage of Participants Who Were HCV Seronegative at 6 Months After Completing Therapy — 59.5; 58.3 percentage of participants
Phase 3 N=36 A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adults With Genotype 1b (GT1b) Infection
Chronic Hepatitis C Virus (HCV) Infection
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks (SVR12) Post-treatment — 100 percentage of participants
Phase 3 N=395 A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
Chronic Hepatitis C Infection
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment — 96.3 percentage of participants
Phase 2 N=146 Infliximab Treatment Along With Pegylated Interferon and Ribavirin in the Treatment of Hepatitis C
Hepatitis C
Primary: A Comparison of the Percentage of Chronic Hepatitis C Subjects (Treatment Naive,Genotype 1) Who Achieve SVR at Week 72, After 48 Weeks of Treatment. — 28.8; 31.5…
N/A N=348 Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Participants With/Without Substitution Therapy (P05255)
Hepatitis C, Chronic
Primary: Number of Participants Who Completed Treatment With PegIFN-2b/Ribavirin — 56; 150 participants
Phase 3 N=286 Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)
Hepatitis C Virus (HCV)
Primary: Percentage of Participants Achieving Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in the Intention-to-Treat (ITT) Population — 96.2 percentage of…
Phase 4 N=377 Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis C
Chronic Hepatitis C
Primary: Sustained Virologic Response (SVR)Rate — 130; 72 participants — p=< 0.001
N/A N=68 Nurse Case Management to Improve Hepatitis C Care in HIV Co-infection
HIV · Hepatitis C, Chronic
Primary: Number of Participants Linked to Care — 8; 16 Participants — p=0.036
Phase 2 N=44 Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients
Hepatitis C Virus Infection
Primary: Mean Log Change in Viral Load From Baseline (Day 1) to Day 28 — 0.30; 0.00; 0.18; 0.04 copies/mL on log scale
Phase 4 N=10 Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and Hepatitis C
Chronic Kidney Disease · Chronic Hepatitis C
Primary: Average Change in Urine Tumor Necrosis Factor (TNF)-Alpha From Baseline to Post-treatment — -0.05 ng/g
N/A N=1,128 Observational Study Assessing Chronic Hepatitis C Management in Clinical Practice in Italy (Study P05488 AM1)
Hepatitis C · Hepatitis C, Chronic
Primary: Number of Participants Not Eligible for Antiviral Treatment by Reason for Non-eligibility — 144; 77; 17; 7 participants
Phase 3 N=302 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection
Chronic Hepatitis C Virus (HCV) Infection
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in Arm A DB Active Drug Excluding Prior SOF + Ribavirin (RBV) ± pegIFN…